Evidence map›Paper›PMID 40072682›Full record

ArticlePurinergic signalling2025

Macrophage P2Y

Aida Collado, Zhichao Zhou

Abstract read
In one paragraph

Article in Purinergic signalling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. P2YPurinergic signalling · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aida ColladoDivision of Cardiology, Department of Medicine Solna, Karolinska Institutet, Solna, Stockholm, 17177, Sweden.
Zhichao ZhouDivision of Cardiology, Department of Medicine Solna, Karolinska Institutet, Solna, Stockholm, 17177, Sweden. zhichao.zhou@ki.se.ORCID http://orcid.org/0000-0002-5107-6529

Funding

the EFSD/Novo Nordisk Foundation Future Leaders Awards NNF22SA0081227the Foundation for Geriatric Diseases 2023-01860the Karolinska Institute KID grant 202100275 and 202301281the Karolinska Institutet grant 202402867 and 202402459the Lars Hierta's Memory Foundation FO2023-0446the Swedish Heart and Lung Foundation 20220264, 20230386 and 20240072the Swedish Research Council 2023-02508Tore Nilson's Foundation for medical research 2024-227
6 · The paper itself

Abstract

Atherosclerosis, a chronic inflammatory disease driven by lipid deposition and immune cell activation, remains a leading cause of cardiovascular morbidity and mortality. Emerging evidence highlights the role of purinergic signalling in atherogenesis, particularly the P2Y

Indexed as

AtherosclerosisMacrophagesReceptors, Purinergic P2Signal TransductionAnimalsHumansMiceMice, Inbred C57BLpurinoceptor P2Y6Receptors, Purinergic P2AtherosclerosisMacrophageP2Y6 receptor

Identifiers

PMID40072682
PMCPMC12722613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.